Business Context and Reporting Period
The supplied filing is Nanophase Technologies Corporation’s audited Form 10-K for the fiscal year ended December 31, 2015—not a quarterly filing. This conflicts with the request metadata naming SOLESENCE, INC.; investors should verify the issuer and filing identity. Nanophase develops and manufactures engineered nano- and sub-micron materials for personal care, coatings, polishing, energy and other applications. Its common stock traded on OTCQB as NANX.
Financial Performance and Liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Total revenue | $10.313 million | $9.936 million |
| Gross profit / margin | $3.114 million / 30.2% | $2.831 million / 28.5% |
| Operating loss | $1.178 million | $1.722 million |
| Net loss | $1.192 million | $1.727 million |
| Operating cash flow | $(240,000) | $(1.181) million |
| Cash and cash equivalents at year-end | $1.275 million | $1.862 million |
Product revenue rose 4.0%; other revenue fell to $41,000 from $56,000. R&D expense was $1.273 million, versus $1.338 million; SG&A was $3.019 million, versus $3.215 million. Investing cash use was $288,000 and financing cash use was $59,000. Year-end current assets were $2.691 million and current liabilities $878,000. The company reported no bank borrowings, but had $238,000 of capital-lease obligations. Accumulated deficit was $93.597 million.
Material Changes Versus 2014
- Revenue increased by $377,000, driven mainly by coatings, medical diagnostics and polishing, partly offset by lower sales to the largest personal-care customer.
- Gross profit increased $283,000 and gross margin improved about 1.7 percentage points; operating and net losses narrowed.
- Cash declined by $587,000, less than the $1.414 million decline in 2014. Lower operating cash use reflected, in part, less working-capital investment.
- Customer concentration eased somewhat: the three largest customers represented 63%, 7% and 7% of revenue in 2015, versus 72%, 1% and 6% for the same customers in 2014.
Outlook, Risks and Unusual Items
Management expected further end-user adoption in 2016 and beyond. New personal-care products using a patented coating began generating revenue in the first quarter of 2016; polishing and energy-management products were described as early-stage growth opportunities. These are expectations, not firm revenue guidance. Management estimated 2016 capital spending of $300,000–$500,000, R&D spending about 6% higher, and SG&A about 6% higher. It expected cash, operating resources and available borrowing capacity to fund planned operations through 2016, while acknowledging financing might not be available on acceptable terms.
- BASF accounted for approximately 63% of 2015 revenue. Its supply agreements permit potential technology licensing and equipment transfer following specified triggering events, including negative trailing earnings combined with cash and certain investments below $1 million. The company reported $1.275 million cash at year-end and raised $988,000 in February 2016 by selling 2.6 million shares to its largest investor.
- Other significant risks include a long customer-adoption cycle, reliance on a small customer base, commodity-metal input costs and rare-earth supply, competition, and the possibility of continued losses or a need for additional capital. Management noted the company had never been profitable and could incur another annual loss in 2016.
- The revolving credit line was extended to March 2017; no amount was outstanding at filing. It permits up to $300,000 or 75% of eligible receivables, whichever is less, subject to conditions.
- The company reported approximately $81 million in tax net operating loss carryforwards, potentially subject to ownership-change limits; the full deferred tax asset was offset by a valuation allowance.
- No material pending litigation was disclosed. Management reported effective disclosure controls and internal control over financial reporting; the auditor gave an unqualified opinion on the financial statements.
Important Facts to Verify
- Confirm that this Nanophase Technologies filing—not a SOLESENCE filing—is the intended document and that the requested period is fiscal year 2015.
- Track quarterly revenue, gross margin and operating cash use against management’s growth and cost-absorption expectations.
- Monitor BASF’s share of sales and the cash threshold and other conditions governing its contractual technology and equipment rights.
- Assess post-year-end liquidity after the February 2016 equity issuance, including dilution and the status and conditions of the credit line.
- Verify whether new personal-care, polishing and energy products produce repeat commercial orders and whether planned capital spending remains within the stated range.